Humanized Anti-Abeta Antibody Dosage Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Alzheimer's disease, particularly those targeting Aβ, face challenges in achieving therapeutic benefits at physiologically safe doses without causing significant side effects, such as vasogenic edema, and there is a need for effective treatments that can inhibit cognitive decline effectively.
Innovation Solution
A humanized version of the mouse antibody 3D6, administered subcutaneously or intravenously at specific dosages and frequencies, is used to maintain optimal serum concentrations of the antibody within a range that maximizes therapeutic benefit while minimizing side effects, specifically targeting the N-terminal fragment of Aβ and monitored for posterior reversible encephalopathy syndrome (PRES) or vascular edema.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of Aβ antibodies are administered to achieve greater therapeutic benefit, then cognitive decline inhibition is improved, but side effects such as vasogenic edema and PRES increase
Solution Approach 1:
The patent applies parameter changes by establishing specific dosage ranges (0.01-0.6 mg/kg subcutaneously or 0.5-1.5 mg/kg intravenously) and administration frequencies (weekly to monthly) to optimize the balance between therapeutic efficacy and safety. This resolves the contradiction by finding the optimal parameter window where cognitive decline is inhibited without triggering severe side effects
Solution Approach 2:
The patent implements feedback mechanisms through monitoring patients for PRES and vascular edema during treatment. Dosage adjustments are made based on observed responses and side effect profiles, allowing the treatment to adapt to individual patient needs while maintaining the balance between therapeutic benefit and safety
2Productivity
If antibody dosage is increased to maximize cognitive decline inhibition, then therapeutic efficacy is improved, but risk of vasogenic edema increases
Solution Approach 1:
The patent resolves this contradiction by defining specific dosage parameters and administration schedules that maximize cognitive benefit while staying below the threshold for edema formation. The established ranges (0.01-0.6 mg/kg subcutaneous, 0.5-1.5 mg/kg intravenous) represent optimized parameters that balance productivity and harm reduction
3Reliability
If antibody concentration is maintained at optimal levels for therapeutic benefit, then cognitive function is preserved, but treatment complexity increases due to monitoring requirements
Solution Approach 1:
The patent applies self-service by establishing fixed dosage regimens and standardized monitoring protocols that guide clinicians through the treatment process. The structured approach with defined dosage ranges and monitoring schedules for PRES and edema reduces the burden of complexity while maintaining optimal antibody concentrations for cognitive preservation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to A-beta. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.